Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
Overview
Latest
Regional
Industry
Featured
Multimedia
Other Languages
Public Company News
All
APAC
Global
All
APAC
Global
All
APAC
Global
All
APAC
Global
{{toptitleLeft}}
{{toptitleRight}}
{{selectTitle}}
{{toptitleLeft}}
{{index}}
{{select_list_per.name}}
Time
{{showName}}
{{weixin_name}}
X
{{listname}}
Loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.headline}}
{{storydata.create_time}}
{{storydata.headline}}
{{storydata.create_time}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
loading
The End
Network Errors Please Retry
The Phase III clinical trial application for first-line treatment of extensive disease small cell lung cancer with Chiauranib has been approved
2024-11-01 19:04
HanAll Biopharma Reports Q3 2024 Financial Results and Provides Business Update
2024-11-01 19:00
Senhwa Biosciences Announces the Appointment of Dr. Yiu-Lian Fong, the Former Global Head of Janssen Diagnostic Innovation and R&D at Johnson & Johnson as the New Corporate Director
2024-11-01 15:28
PharmaResearch Hosts 5th Global Symposium on 'Rejuran'
2024-11-01 14:01
Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combination as First-Line Therapy for Biliary Tract Tumors, Compared to Durvalumab
2024-11-01 11:34
CARsgen® U.S. Clinical Holds Lifted by FDA
2024-11-01 09:33
Formosa Pharmaceuticals and DÁVI Farmacêutica Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Post-Operative Inflammation and Pain
2024-10-31 21:36
The One-Year Outcome of LuX-Valve Plus TRAVEL II Study was Officially Released at TCT 2024
2024-10-31 21:00
Ping An Health Achieves WONCA International Quality Dual Certifications Defining New Standards in Internet Healthcare Services
2024-10-31 20:14
Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology
2024-10-31 20:00
I-Mab to Release Q3 2024 Financial Results on November 14, 2024
2024-10-31 19:00
Cancer trial: retraining immune cells offers new hope for patients in personalized medicine breakthrough
2024-10-31 18:00
ZYMFENTRA® (infliximab-dyyb) coverage continues to increase through partnership with top 3 Pharmacy Benefit Managers (PBMs)
2024-10-31 14:31
Kelun-Biotech's TROP2-ADC SKB264 (sac-TMT) Third NDA Accepted by NMPA, locally advanced or metastatic EGFR-mutant NSCLC
2024-10-31 12:02
MGI's DNBSEQ-T20 x2 Selected As A Special Mention In TIME Best Inventions 2024
2024-10-31 10:51
Abionic's CAPSULE PSP Receives FDA Approval for Early Detection of Sepsis; Fapon Introduces Exclusive PSP Solution in China via Licensing Collaboration
2024-10-31 10:26
Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combined with Ligufalimab (CD47) for First-Line Treatment of Head and Neck Squamous Cell Carcinoma (HNSCC), Compared to Pembrolizumab
2024-10-31 08:46
Neurophet partners with Beijing LADO Technology… Intends to establish Joint Venture in China
2024-10-30 21:00
I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024
2024-10-30 19:00
World Stroke Congress | TASTE-2 significantly reduces stroke disability
2024-10-30 15:36
1
2
3
4
5
429